Unicycive Therapeutics’ (UNCY) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note published on Wednesday morning,Weiss Ratings reports.

Several other research analysts have also issued reports on the company. Benchmark raised their price target on Unicycive Therapeutics to $21.00 and gave the stock a “speculative buy” rating in a research report on Monday, September 15th. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $4.44 on Wednesday. The firm has a market capitalization of $78.41 million, a price-to-earnings ratio of -1.08 and a beta of 1.86. The business’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $5.24. Unicycive Therapeutics has a 52 week low of $3.53 and a 52 week high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.18. As a group, research analysts forecast that Unicycive Therapeutics will post -0.23 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UNCY. Vivo Capital LLC raised its stake in shares of Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock valued at $6,537,000 after purchasing an additional 1,400,000 shares during the period. JPMorgan Chase & Co. increased its position in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics in the second quarter valued at about $55,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.